Company: DTCK
Filing Date: 2025-03-21
Form Type: 6-K
Source: 0001683168-25-001763
Chunk: 0

Company: DAVIS COMMODITIES Ltd
Filing Date: 2025-03-21
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16

OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2025

Commission File Number: 001-41804

Davis Commodities Limited

10 Bukit Batok Crescent, #10-01, The Spire

Singapore 658079

(Address of principal executive office)</div>

Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐</div>

<div align='center'>INFORMATION CONTAINED IN THIS FORM 6-K REPORT</div>

On March 19, 2025, Davis Commodities Limited (the
“Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying
the Company that based on the closing bid price of the Company for the period from February 3, 2025 to March 18, 2025, the Company no
longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1
per share.

The notification has no immediate effect on the
listing of the Company’s ordinary shares. Nasdaq has provided the Company with a 180 calendar days compliance period, or until September
15, 2025, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance
in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing
requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception
of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance
period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency,
or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities will be subject to delisting.

The Company is currently evaluating options to
regain compliance